Diabetes Week


Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions



Diabetes Week Library
Library Home

This article was published in Diabetes Week, which you can subscribe to online.
2007 JUL 9 -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced that abstracts related to Sulonex(TM) (sulodexide oral gelcap) have been selected for publication or presentation during the poster sessions scheduled to take place at the upcoming American Diabetes Association (ADA) 67th Annual Scientific Sessions and exposition at the McCormick Place Lakeside Center in Chicago, Illinois.

Copies of these abstracts, which highlight the mechanism of action of Sulonex(TM) as well as observed clinical activity, are currently available and can be viewed on-line through the ADA website: http://scientificsessions.diabetes.org/index.cfm?fuseaction=3DLocator.DisplaySea rchAbstract&CalledByID=3D1006

Keywords: Biotechnology Business, Biotechnology Company, Diabetes, Keryx Biopharmaceuticals, Nanotechnology Company, Pharmaceutical Business, Pharmaceutical Company, Pharmaceuticals, Keryx Biopharmaceuticals Inc.

This article was prepared by Diabetes Week editors from staff and other reports. Copyright 2007, Diabetes Week via NewsRx.com.